This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Pharmahungary Group has announced it will be participating in a project aiming to set up standardised methods to examine intercellular and interorgan communication via extracellular vesicles, the next Big thing in the diagnosis and therapy of cancer and cardiovascular diseases
Swiss Alentis Therapeutics has raised US$181.4m in an oversubscribed Series D financing set to boost clinical development of its anti-Claudin-1 ADCs in solid tumours.
Swiss Alentis Therapeutics has raised US$181.4m in an oversubscribed Series D financing set to boost clinical development of its anti-Claudin-1 ADCs in solid tumours.
Biotech CSOs, CDMOs, CROs, lab specialists and AI developers gave an in-depth insight into next-generation antibody-based therapies to about 1,500 attendees at the 16th PEGS Europe in Barcelona. Several new formats are expected to enter the market in the next few years, promising to significantly reduce the side effects of CAR-Ts, bispecific antibodies, ADCs, etc. and improve their efficacy.
US spin-out of German MPI for molecular genetics, Harbinger Health Inc, has started a collaboration with Memorial Sloan Kettering Cancer Centre to turboboost recruiting for its Core-HH study. The study aims to validate a blood test that predicts tumour developement in cancer stage I.
Novo Nordisk is putting down up to US$362m to tap into Ascendis’ TransCon technology for treatments in metabolic and cardiovascular diseases. The pharma powerhouse has its sights set on developing a once-monthly GLP-1 receptor agonist.
The Strasbourg-based biotech company Transgene and the Berlin-based CDMO ProBioGen have entered into a licensing agreement to collaboratively advance the development of individualised cancer vaccines.
In both, liver fibrosis and resolution of MASH, Novo Nordisk’s GLP1 modulator semaglutide has shown convincing results in the Phase III ESSENCE study suggesting a label extension of the obesity blockbuster.
Radiopharmaceuticals specialist Blue Earth Therapeutics Ltd will use a U$76.5m Series A financing to finance Phase II development of its targeted prostate cancer radiopharmaceuticals Lutetium (177-Lu) rhPSMA-10.1 and Actinium (225-Ac) rhPSMA-10.1.
As the first Nordic company seeking Novel Food approval for a mycoprotein ingredient, Finnish Enifer has filed a authorisation application for it brand PEKILO to the EU food watchdog EFSA.